Bulletin from the Annual General Meeting in Enzymatica AB (publ)

Regulatory information
Press release
Lund on 25 May 2016

Press release
Lund on 25 May 2016                                                                         

Today on 25 May 2016, the Annual General Meeting was held in Enzymatica AB (publ). A summary of the resolutions adopted follows below. All resolutions were adopted unanimously.

Appropriation of profit/loss
The Annual General Meeting voted in favor of adopting the income statement and the balance sheet of the group and parent company and resolved to carry forward the funds available at the Annual General Meeting and, consequently, resolved not to distribute any dividend for the financial year 2015.

Discharge from liability for the members of the Board of Directors and the CEO
The Annual General Meeting resolved to discharge the Board of Directors and the CEO from liability for the financial year 2015.

Election of Board of Directors and auditor
In accordance with the Nomination Committee's proposal, the Annual General Meeting resolved to re-elect Lennart Nilsson, Marianne Dicander Alexandersson, Hans Pihl, Nils Siegbahn, Monica Wallter, Guðmundur Pálmason and Sigurgeir Guðlaugsson. Lennart Nilsson was re-elected as the Chairman of the Board of Directors.

The Annual General Meeting further resolved to appoint Ernst & Young AB as the company's auditor until the end of the next Annual General Meeting.

Remuneration to the Board of Directors
The Annual General Meeting resolved that remuneration for the Board of Directors, excluding remuneration for committee work, shall be paid with a total of SEK 900,000, of which SEK 180,000 is remuneration for the Chairman of the Board of Directors and SEK 120,000 to every other member of the Board of Directors. In addition, remuneration for work in the Audit Committee shall be paid with SEK 50,000 to the Chairman of the Audit Committee and no remuneration shall be paid to other members of the Audit Committee. Further, no remuneration shall be paid for work in the Remuneration Committee.

Principles for the Nomination Committee
The Annual General Meeting resolved to adopt principles for the Nomination Committee for upcoming elections and remuneration. The Nomination Committee shall be comprised of representatives appointed by the four largest shareholders as of 31 October, together with the Chairman of the Board of Directors.

Guidelines for remuneration for senior executives
The Annual General Meeting further resolved to adopt guidelines for remuneration for senior executives, including a fixed salary and, from time to time, variable payments for rewarding target-related performances.

Authorisation of the Board of Directors to issue new shares
The Annual General Meeting resolved to authorise the Board of Directors until the next annual shareholders' meeting to, on one or more occasions, resolve to increase the Company's share capital by issue of no more than 17,500,000 new shares, with or without deviation from the shareholders' preferential rights. The reason for the board of directors' authorisation to deviate from the shareholders' preferential rights is to enable the company's possibilities to raise new capital and to take advantage of future opportunities to attract new long-term owners of strategic importance to the company, as well as to finance the Company's growth strategy.

All resolutions by the Annual General Meeting were adopted unanimously.

For more information, please contact:

Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com

About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.   

Enzymatica's certified advisor is Erik Penser Bankaktiebolag.

Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.